Major Shareholder Buying Shares
Jan 09, 2017 13:02 pm UTC| Business
TEL AVIV, Israel, Jan. 09, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology announces today that it has received notice, from one of the Company’s major...
Major Shareholder Buying Shares
Jan 09, 2017 13:02 pm UTC| Business
TEL AVIV, Israel, Jan. 09, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology announces today that it has received notice, from one of the Company’s major...
Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017
Jan 09, 2017 13:02 pm UTC| Business
WALTHAM, Mass., Jan. 09, 2017 -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate review of 2016 and...
Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017
Jan 09, 2017 13:02 pm UTC| Business
WALTHAM, Mass., Jan. 09, 2017 -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate review of 2016 and...
Live Ventures Incorporated Issues Letter to Stockholders
Jan 09, 2017 13:02 pm UTC| Business
LAS VEGAS, Jan. 09, 2017 -- Live Ventures Incorporated (Nasdaq:LIVE) (“Live Ventures” or the “Company”), a diversified holding company, distributed the below Letter to its stockholders this morning: Dear Stockholders,...
Live Ventures Incorporated Issues Letter to Stockholders
Jan 09, 2017 13:02 pm UTC| Business
LAS VEGAS, Jan. 09, 2017 -- Live Ventures Incorporated (Nasdaq:LIVE) (“Live Ventures” or the “Company”), a diversified holding company, distributed the below Letter to its stockholders this morning: Dear Stockholders,...
Jan 09, 2017 13:02 pm UTC| Business
-- Expands Allergan’s Innovative GI Pipeline with ABI-M201 and ABI-M301, Preclinical Compounds Targeting Ulcerative Colitis and Crohn’s Disease, as well as Future Compounds for Irritable Bowel Syndrome -- DUBLIN,...